Your browser doesn't support javascript.
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
Lei, Zi-Ning; Wu, Zhuo-Xun; Dong, Shaowei; Yang, Dong-Hua; Zhang, Litu; Ke, Zunfu; Zou, Chang; Chen, Zhe-Sheng.
  • Lei ZN; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: zining.lei14@stjohns.edu.
  • Wu ZX; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: zhuoxun.wu17@stjohns.edu.
  • Dong S; Key Laboratory of medical electrophysiology of education ministry, School of Pharmacy, Southwest Medical University, China; Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Southern University of Science and Technology, Shenzhen 518020, Guangdong, China.
  • Yang DH; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: yangd1@stjohns.edu.
  • Zhang L; Department of Research, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
  • Ke Z; Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, China. Electronic address: kezunfu@mail.sysu.edu.cn.
  • Zou C; Key Laboratory of medical electrophysiology of education ministry, School of Pharmacy, Southwest Medical University, China; Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Southern University of Science and Technology, Shenzhen 518020, Guangdong, China. Electron
  • Chen ZS; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: chenz@stjohns.edu.
Pharmacol Ther ; 216: 107672, 2020 12.
Article in English | MEDLINE | ID: covidwho-997417
ABSTRACT
Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades. As their new mechanisms of actions are identified in recent years, CQ and HCQ have wider therapeutic applications, one of which is to treat viral infectious diseases. Since the pandemic of the coronavirus disease 2019 (COVID-19), CQ and HCQ have been subjected to a number of in vitro and in vivo tests, and their therapeutic prospects for COVID-19 have been proposed. In this article, the applications and mechanisms of action of CQ and HCQ in their conventional fields of anti-malaria and anti-rheumatism, as well as their repurposing prospects in anti-virus are reviewed. The current trials and future potential of CQ and HCQ in combating COVID-19 are discussed.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Chloroquine / Coronavirus Infections / Antirheumatic Agents / Betacoronavirus / Antimalarials Limits: Animals / Humans Language: English Journal: Pharmacol Ther Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Chloroquine / Coronavirus Infections / Antirheumatic Agents / Betacoronavirus / Antimalarials Limits: Animals / Humans Language: English Journal: Pharmacol Ther Year: 2020 Document Type: Article